Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,227 shares of the company’s stock after selling 282 shares during the period. Avior Wealth Management LLC’s holdings in Neurocrine Biosciences were worth $557,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. FCF Advisors LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $1,157,000. Redhawk Wealth Advisors Inc. acquired a new position in Neurocrine Biosciences during the 4th quarter valued at about $1,245,000. Nordea Investment Management AB grew its position in Neurocrine Biosciences by 205.7% in the 3rd quarter. Nordea Investment Management AB now owns 28,591 shares of the company’s stock worth $3,279,000 after purchasing an additional 19,238 shares during the last quarter. DekaBank Deutsche Girozentrale grew its position in Neurocrine Biosciences by 28.3% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 69,596 shares of the company’s stock worth $9,138,000 after purchasing an additional 15,367 shares during the last quarter. Finally, Teza Capital Management LLC acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $1,442,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the completion of the sale, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,088,965.42. The disclosure for this sale can be found here. Insiders have sold 196,994 shares of company stock valued at $27,205,009 over the last three months. 4.40% of the stock is currently owned by insiders.

Neurocrine Biosciences Trading Down 0.5 %

NBIX stock opened at $132.54 on Friday. Neurocrine Biosciences, Inc. has a one year low of $89.04 and a one year high of $148.37. The firm has a market capitalization of $13.19 billion, a PE ratio of 54.77 and a beta of 0.25. The firm has a 50-day moving average of $136.16 and a two-hundred day moving average of $126.85.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. Barclays increased their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Wells Fargo & Company increased their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a research report on Thursday, February 8th. Finally, Wedbush restated an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $139.67.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.